Statins have been approved to benefit patients underwent percutaneous coronary intervention (PCI). The current study is designed to evaluate the effectiveness and safety of Sequential Therapy of Atorvastatin in patients with ST-elevated myocardial infarction and receive PCI treatment.

Inclusion Criteria:

• Sighed informed consent
• Diagnosised as acute myocardial infarction
• Time frame less than 12 hours since the occurance of chest pain
• Aggred to receive sirolimus-eluted coronary stents
• Patients willing to accepte follow-up

Exclusion Criteria:

• Allegy to statins or with a history against statin therapy
• Allegy to any products that will be used during PPCI
• Disagreed to receive PPCI and other related therapy
• Existing sever liver dysfuntion that statins can not be used according to the guildlines
• Sever kidney dysfunction (creatinine >3mg/dl or eGFR<30ml/min)
• Sever left ventricular dysfunction (Killip grade 3)
• Patients are currently taking medicine that may influence the use of statin
• Patients with a history of alcohol abuse or durg abuse
• Woman during pregnancy or lactation
• Patients who has attended other clinical trials
• Patients who has received PCI or CABG previously
• Patients who can not agree to accept study protocol
• Other conditions that may not sutible for the current study